Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity was originally published by The Motley Fool ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no ...

While biotech stocks have a reputation for being perilous investments, you can reduce your risk by identifying companies that have healthy balance sheets and diverse portfolios of advanced drug ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Sagimet Biosciences eyes major opportunities in MASH and Acne treatments. Find out why SGMT stock is a solid pick with upcoming phase 3 study results.